01 April 2025 : Clinical Research
Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye
Melike Yüksel Yavuz
ABCDEF 1*, Filiz Karapinar ABDE 2, Ceyda Anar DEF 3, Mehdi Ok CD 2, Sema Ertürk CD 4, Mine Gayaf DEF 2, Fatma Demirci Üçsular DEF 2, Gülru Polat DEF 2
DOI: 10.12659/MSM.947817
Med Sci Monit 2025; 31:e947817
Table 2 Histology, cancer stage, ECOG, ICI agents, and PDL-1 levels of patients.
| n | % | ||
|---|---|---|---|
| Histology (N=100) | Adenocarcinoma | 63 | 63.0 |
| SCC | 33 | 33.0 | |
| Other | 4 | 4.0 | |
| Staging (N=100) | 2b | 1 | 1.0 |
| 3a | 2 | 2.0 | |
| 3b | 7 | 7.0 | |
| 3c | 9 | 9.0 | |
| 4 | 81 | 81 | |
| ECOG performance score (N=100) | 0 | 43 | 43.0 |
| 1 | 34 | 34.0 | |
| 2 | 22 | 22.0 | |
| 3 | 1 | 1.0 | |
| ICI dose Ort±SD | 14.9±9.3 | ||
| PD-L1 expiratory level (N=100) | Unreachable | 46 | 46.0 |
| Negative | 34 | 34.0 | |
| Weak Positive | 8 | 8.0 | |
| Strong positive | 12 | 12.0 | |
| ICI (N=100) | Nivolumab | 99 | 99.0 |
| Atezolizumab | 1 | 1.0 | |
| Chemotherapy (N=100) | No | 1 | 1.0 |
| Yes | 98 | 99.0 | |
| Radiotherapy (N=100) | No | 17 | 17.0 |
| Yes | 83 | 83.0 | |
| ECOG – Eastern Cooperative Oncology Group; PDL-1 – programmed cell death ligand-1; ICI – immune checkpoint inhibitors; SCC – squamous cell carcinoma. | |||